Urgent

Familial Mediterranean fever (FMF) & hereditary periodic fever syndromes (autoinflammatory)

Familial Mediterranean fever · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

The commonest monogenic autoinflammatory disease — autosomal recessive MEFV (pyrin) mutation, most frequent in Mediterranean, Middle-Eastern, Armenian, Turkish, Sephardic Jewish and some Indian populations. Recurrent self-limiting attacks (12-72 h) of FEVER with serositis: sterile peritonitis (severe abdominal pain mimicking surgical abdomen), pleuritis, synovitis (monoarthritis) and an erysipelas-like rash on the lower leg/ankle. Attacks resolve spontaneously but recur. The major long-term threat is AA (secondary) amyloidosis causing renal failure. Lifelong colchicine both prevents attacks and prevents amyloidosis. (Other periodic fevers: TRAPS, CAPS, HIDS/MKD, PFAPA — considered when colchicine fails or in non-FMF ethnicities.)

Red flags

  • First presentation with acute abdomen — do not assume FMF; exclude surgical cause before labelling
  • New proteinuria/nephrotic syndrome/renal impairment — AA amyloidosis (the key long-term threat)
  • Colchicine overdose features (profuse diarrhoea, vomiting, pancytopenia, multi-organ failure) — potentially fatal, even small excess
  • Severe toxicity when colchicine combined with clarithromycin/statins/ciclosporin
  • Attacks every month despite maximal colchicine — colchicine resistance, needs IL-1 blockade

Assessment

Differential diagnosis

  • Acute surgical abdomen (appendicitis, perforation) — FMF peritonitis is sterile but mimics it; past identical self-limiting episodes are the clue
  • Other periodic fevers: TRAPS (longer attacks, periorbital oedema), CAPS (cold-induced urticaria, deafness), HIDS/mevalonate kinase deficiency (high IgD, cervical nodes), PFAPA
  • Adult-onset Still disease (quotidian fever, evanescent rash, very high ferritin)
  • Systemic JIA; cyclical/recurrent infection; inflammatory bowel disease
  • Acute intermittent porphyria (recurrent abdominal pain)

Investigations

  • MEFV genetic testing (confirms FMF; M694V = severe phenotype/higher amyloid risk)
  • Acute-phase reactants DURING and BETWEEN attacks: CRP, ESR, SAA (serum amyloid A — key for amyloid risk), fibrinogen
  • FBC (neutrophilia during attack); exclude surgical/infective cause (lactate, imaging) on first presentation
  • Urinalysis for PROTEINURIA + urine protein:creatinine — surveillance for AA amyloidosis (renal)
  • IgD / mevalonate kinase, and gene panel if atypical/colchicine-resistant (other periodic fevers)

Management

  • Recognise the pattern: recurrent short febrile serositis attacks + compatible ethnicity + family history; confirm with MEFV genetics
  • On first acute attack exclude a true surgical/infective abdomen before attributing to FMF
  • Acute attack: supportive — NSAIDs/analgesia; colchicine does NOT abort an established attack but is continued
  • Start lifelong daily COLCHICINE — prevents attacks AND prevents amyloidosis; do not stop even if attacks controlled (amyloid protection)
  • Uptitrate colchicine to maximum tolerated dose; counsel strict adherence; monitor for diarrhoea/myopathy and interactions (clarithromycin, statins, ciclosporin — colchicine toxicity)
  • Colchicine resistance (>=1 attack/month on max tolerated dose for 6 months) or intolerance: add IL-1 inhibitor (anakinra or canakinumab)
  • Monitor SAA/CRP between attacks and urine protein — target normalised SAA to prevent amyloidosis
  • Genetic counselling; consider other periodic fever syndromes if colchicine ineffective or non-FMF ethnicity

Drugs & doses

Colchicine 1-1.5 mg ORALLY daily (single or divided), uptitrate to max tolerated ~2-3 mg/day (lower in renal impairment); paediatric weight-based — LIFELONG [verify local dose]
NSAID e.g. ibuprofen/naproxen for symptomatic relief of acute attack fever/serositis [verify local dose]
Anakinra (IL-1 receptor antagonist) 100 mg SC daily for colchicine-resistant disease (dose-reduce/space in renal failure) [verify local]
Canakinumab (anti-IL-1beta) 150 mg SC every 4-8 weeks for colchicine-resistant disease [verify local]
AVOID potent CYP3A4/P-gp inhibitors with colchicine (clarithromycin, ketoconazole, ciclosporin) — fatal colchicine toxicity; reduce colchicine or avoid [verify local]

Disposition

Outpatient rheumatology for diagnosis + lifelong colchicine. ED: exclude surgical abdomen, analgesia, refer. Admit for suspected amyloidosis complications or colchicine toxicity.

Complications & pitfalls

  • AA (secondary) amyloidosis -> nephrotic syndrome and end-stage renal failure (main cause of mortality)
  • Chronic arthritis; infertility/subfertility (improved by colchicine)
  • Peritoneal adhesions from recurrent serositis
  • Colchicine toxicity (especially with interacting drugs/renal impairment)

Exam pearls

  • Colchicine is lifelong and prevents amyloidosis — never stop it just because attacks are controlled; adherence is the single most important determinant of outcome.
  • Colchicine does not abort an established attack — it is prophylactic; manage the acute attack with analgesia/NSAIDs.
  • Monitor serum amyloid A (SAA) and urine protein — persistently high SAA signals ongoing amyloid risk even if asymptomatic.
  • IL-1 inhibitors (anakinra/canakinumab) are the answer for colchicine resistance (EULAR/PReS 2016, updated 2025).
  • Beware fatal colchicine toxicity with clarithromycin, statins, ciclosporin and in renal impairment — adjust/avoid.
  • On a first 'surgical' abdomen in a young person of relevant ethnicity with prior identical self-limiting episodes, think FMF.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.